Cardihab being used in a world leading long COVID study

Cardihab being used in a world leading long COVID study

Cardihab being used in a world leading long COVID study

Today the Baker Heart and Diabetes Institute announced a world leading investigation into the long-term heart damage caused by COVID-19. Hundreds of Melbourne COVID-19 survivors are being recruited for the study looking into the effects of what is dubbed "long COVID" — where those who have previously tested positive report complications months after they have recovered.

We are incredibly proud that the Cardihab platform will be utilised in this study to support patients in their disease management and recovery.

Read the announcement on 9News:

Hundreds of Melbourne COVID-19 survivors to participate in groundbreaking 'long COVID' study — 9News (baker.edu.au)

For more information on the study please visit the Baker Institute website: https://lnkd.in/gfSchpV

ImpaQT Group's support and investment in Cardihab

Cardihab are delighted to have ImpaQT Group investment

We are delighted to have the ImpaQT Group's support and investment to help us to fulfil our mission of improving access to care for patients recovering from cardiac events and/or living with heart disease.

The power of digital health in addressing cardiovascular disease management and treatment can only be achieved via a collaborative effort with healthcare professionals and patients, and for early stage companies like ours, with the generous support from investors like the ImpaQT Group who share our vision to deliver outcomes that will make a meaningful difference.

Thank you Lisa Siganto and the team at ImpaQT Group, and to all everyone contributing to the ImpaQt Fund.

https://lnkd.in/g4Wzs4v

The Baker Institute and Cardihab collaborate to deliver new digital heart disease prevention and management approaches

baker and cardihab collaboration

Digital health will take transformative steps by supporting new clinical trials to address secondary prevention of Australia’s deadliest disease following an agreement between Australian digital health company Cardihab and medical research organisation, the Baker Heart and Diabetes Institute.

The five-year agreement between Cardihab and the Baker Institute will involve several clinical trials and cohort studies that provide evidence of the effectiveness of digital approaches to cardiovascular disease management, rehabilitation, prevention and treatment.

Cardihab is a landmark Australian digital health platform that facilitates the virtual delivery of cardiac rehabilitation and chronic disease management programs for patients recovering from cardiac events and living with heart disease.

Patients use Cardihab apps to complete their cardiac rehabilitation program virtually while under clinical supervision by qualified healthcare professionals.

Cardihab Chief Executive Officer Helen Souris said it was the first widespread research program to be conducted in Australia using broader applications of Cardihab’s digital health platform.

“The outcomes of these clinical trials and studies will impact on the lives of more than 4.2 million people with heart or vascular disease around the country,” Ms Souris said.

“It will further demonstrate how digital health is delivering options for rehabilitation and secondary prevention that improve patient choice leading to greater uptake and better outcomes.

“Digital solutions that empower patients to proactively manage their health while reducing the pressure on hospitals and staff are essential given the burden of disease and vulnerability of patients, particularly during COVID-19 constraints. Clinically validated digital health programs are vital for people who cannot attend traditional face-to-face clinics, people living in regional and remote areas and patients who are less mobile.”

The clinical trials will also facilitate world-leading research into the application of digital cardiac rehabilitation in new areas such as cardio-oncology.

Ms Souris said there was a significant need for risk-guided rehabilitation programs for people who survive cancer but develop cardiovascular disease associated with cancer treatment.

As cancer therapies and survival have improved, millions of patients treated with cardiotoxic therapy are now cancer survivors1.  In Australia, cardiovascular disease is the leading cause of non-cancer death in cancer survivors2, and 8per cent of deaths are from heart failure (HF), which occurs in 18per cent of cancer survivors.

“There are a number of cardioprotective strategies that can be implemented to support patients during and after their cancer treatment,” Ms Souris said. “Risk-guided Digital cardiac rehabilitation as part of a program of care could be an effective solution that helps manage heart problems in cancer patients and assist in improving their quality of life,” Ms Souris said.

“Digital solutions such as Cardihab will enable clinicians to deliver individualised and tailored support for cancer patients at risk with the ability to monitor their care without the need for regular face-to-face consultations.”

Baker Heart and Diabetes Institute Professor Tom Marwick said the Institute was committed to secondary prevention and ensuring people who had a cardiovascular event like a heart attack did not suffer another one.

Solutions which support patients to self-manage chronic long-term conditions such as cardiovascular disease, particularly during challenging COVID-19 lockdowns, are important, Professor Marwick said.

“The evidence shows that cardiac rehabilitation optimises patient outcomes and reduces cardiovascular risks, and we need to make it as easy and accessible as possible to ensure participation.”


About the Baker Heart and Diabetes Institute

The Baker Heart and Diabetes Institute is based in Melbourne and has made pioneering discoveries to enhance the diagnosis, treatment and prevention of cardiovascular disease, diabetes and related conditions for 95 years.

 1 De Sanctis C SR, Jemal A. <cancer-treatment-and-survivorship-facts-and-figures-2014-2015.pdf>.  

2 Ye Y, Otahal P, Marwick TH, Wills KE, Neil AL, Venn AJ. Cardiovascular and other competing causes of death among patients with cancer from 2006 to 2015: An Australian population-based study. Cancer 2019;125:442-452.

How digital solutions to cardiac rehabilitation are transforming patient outcomes webinar

Webinar recording: How digital solutions to cardiac rehabilitation are transforming patient outcomes

The pioneering collaboration between Cardihab, the Tasmanian Health Service and the Royal Flying Doctors Service Tasmania for a state-wide digital cardiac rehabilitation solution received significant interest from consumers and health services providers Australia wide, and significant uptake by the media at the launch event in March this year.

In response to this interest, the Australian Healthcare and Hospitals Association (AHHA) hosted a webinar to showcase this pioneering program and provide an opportunity for Q&A on the potential patient outcomes this collaboration could deliver.

The recording of the webinar can now be accessed:
How digital solutions to cardiac rehabilitation are transforming patient outcomes

Cardihab’s recent raise campaign via the VentureCrowd crowd funding platform

Crowdfunding a heart-starter for stalled ventures

Cardihab’s recent raise campaign via the VentureCrowd crowd funding platform caught the interest of journalist Jonathan Porter from the Australian Financial Review. This article talks to the emerging trend of crowd funding to support start-ups in Australia and shares our story and points to consider as we decided on this path.

Jonathan Porter Jun 17, 2021 -  Learn more
Cardihab’s recent raise campaign via the VentureCrowd crowd funding platform
The Australian first partnership between Uniseed and VentureCrow

The Australian first partnership between Uniseed and VentureCrowd and the benefits for Cardihab

The Australian first partnership between Uniseed and provides an important pathway for wholesale investors to support the growth and expansion of home grown digital health companies like Cardihab to achieve our potential.

The digitisation of important health services like cardiac rehabilitation is critically needed in Australia and around the world, with 80% of eligible patients currently missing out.

We are honoured to be the first company profiled through this partnership, and expect more to follow.  Learn more

1621975822420
How digital solutions to cardiac rehabilitation are transforming patient outcomes webinar

Webinar: How digital solutions to cardiac rehabilitation are transforming patient outcomes

The pioneering collaboration between Cardihab, the Tasmanian Health Service and the Royal Flying Doctors Service Tasmania for a state-wide digital cardiac rehabilitation solution received significant interest from consumers and health services providers Australia wide, and significant uptake by the media at the launch event in March this year. In response to this interest, the Australian Healthcare and Hospitals Association (AHHA) will host a webinar to showcase this pioneering program and provide an opportunity for Q&A on the potential patient outcomes this collaboration could deliver.

A link to details about the webinar is here:

Webinar: How digital solutions to cardiac rehabilitation are transforming patient outcomes | Australian Healthcare & Hospitals Association (ahha.asn.au)

A link to our LinkedIn Post for the event is here:

https://www.linkedin.com/posts/helen-souris-30ba4727_webinar-how-digital-solutions-to-cardiac-activity-6795200458140065792-xVce

WEBINAR

Mike O’loughlin speaks with Helen Souris, CEO of Cardihab

Tassie Talks LAFM Host Michael O’Loughlin interviews Helen Souris CEO Cardihab.

The Tasmanian government is the first state that’s taken an important step towards digital health with a new partnership with Cardihab and the Royal Flying Doctors Service Tasmania to provide digital cardiac rehabilitation services in public hospitals across the state.